CPC-060 Follow-Up of Patients Treated by Prolonged-Release Olanzapine in a Psychiatric Hospital

@inproceedings{Aldeguer2013CPC060FO,
  title={CPC-060 Follow-Up of Patients Treated by Prolonged-Release Olanzapine in a Psychiatric Hospital},
  author={Alejandro Aldeguer and Corinne Peloso and C Moutonnier and Olivier Canceil and Betty Garnier and M. N. Vacheron and Emmanuelle Advenier-Iakovlev},
  year={2013}
}
Background Olanzapine is an atypical antipsychotic. Available in France since 2010, olanzapine pamoate (OP) is a prolonged-release suspension for intramuscular (IM) injection. OP is effective in the treatment of schizophrenic patients previously stabilised by oral olanzapine, and has been developed to improve compliance in these patients. In France, the injection must be performed in a psychiatric hospital department with 3-hour monitoring due to the potential ‘post-injection syndrome… CONTINUE READING

Similar Papers

Topics from this paper.